In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Delivery in a Product-Oriented World

Executive Summary

Drug delivery companies trend below other biopharma companies in average alliance values, but do slightly better on the IPO market.

You may also be interested in...



Carigent Therapeutics Inc.

Carigent Therapeutics' novel nanoparticle targeted drug delivery technology allows for controlled release of therapeutic agents, targeting drugs to a particular physiological site, tethering of surface ligands, and the ability to combine multiple agents--like imaging agents and drugs--into one vehicle. The foundation of the platform is an FDA-approved biocompatible and biodegradable polymer material, PLGA, which is made into particles at the nano- or micro-scale depending on the application.

PharmaKodex Ltd.

PharmaKodex, a joint venture of Vectura Group and Unilever Ventures, is developing oral and dermal delivery systems that improve availability, thus improving drug response time and activity, leading to greater patient acceptance. The company is adding a twist to the standard low-risk reformulation model now ubiquitous in the specialty pharma world; it intends to use its technologies to develop OTC drugs that will hit market faster and bring in revenue to fund prescription drug development.

Macromolecules & Spec Pharma: The Good News in Drug Delivery

Two major changes have transformed the prospects for drug-delivery companies: the rise of spec pharma and Big Pharma's embrace of large-molecule therapeutics. A new group of start-ups represents strategies to take advantage of both opportunities.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel